N-glycan shielded CUB domains of ADAMTS13 prevent binding of C-terminal antibodies in patients with immune-mediated TTP. [PDF]
Postmus T +9 more
europepmc +1 more source
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients [PDF]
core +1 more source
Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy. [PDF]
Tanaka H +9 more
europepmc +1 more source
Thrombotic Thrombocytopenic Purpura and Evans Syndrome: Validating and Exploring 20 Years of Routine Hospital Care. [PDF]
Lawrie DA +15 more
europepmc +1 more source
Hemolytic uremic syndrome with Mycoplasma pneumoniae infection and membrane cofactor protein mutation [PDF]
Csuka, Dorottya +5 more
core
A predictive algorithm involving lactate dehydrogenase to serum creatinine ratio may assist in identifying patients with thrombotic thrombocytopenic purpura. [PDF]
Chen X +8 more
europepmc +1 more source
Daratumumab in relapsed or refractory immune thrombocytopenic purpura. [PDF]
Tomuleasa C, Gale RP.
europepmc +1 more source
Immune-coagulation dynamics in severe COVID-19 revealed by autoantibody profiling and multi-omics integration. [PDF]
Ambikan AT +8 more
europepmc +1 more source
Relationship Between COVID-19 and Retinal Vein Occlusions. [PDF]
Muto T, Machida S, Imaizumi S, Kamoi K.
europepmc +1 more source
The third form of thrombotic thrombocytopenic purpura shows up again: what is it, does it even exist, how to find out? Comment on "Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism" and on "The different faces of thrombotic thrombocytopenic purpura". [PDF]
Lämmle B.
europepmc +1 more source

